Ascendis

Ascendis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Established in 2015, Ascendis is a full-service Strategy, Design and Technology firm with offices in Montreal and Toronto. Our mission is to empower bold leaders to grow their business by developing forward-thinking strategies and creating products, services and experiences that people love. To date, we have successfully advised over 250 companies across a broad variety of industries. Our service offering includes: Strategic Consulting - we help our clients develop progressive strategies and pragmatic actions plans to drive sustainable and profitable growth for your business. Insight & Foresight - we help our clients gain an intimate understanding of your customer, evaluate market opportunities and develop long-term strategic vision. Experience Design - we help our clients create products, services and experiences that resonate with your customers, through human-centred design. Technology Platforms - we help our clients make forward-thinking technology decisions and develop scalable digital products and platforms. We are a Salesforce, ServiceNow and Shopify integration Partner. Visit our website to learn about our service offering, clients and leadership team: www.ascendis.ca

Company Details

Employees
45
Founded
-
Address
2055 Peel Street, Suite 1100,canada
Industry
Business Consulting And Services
NAICS
Management, Scientific, and Technical Consulting Services
Management Consulting Services
Other Scientific and Technical Consulting Services
Other Management Consulting Services
HQ
Montreal, QC
Looking for a particular Ascendis employee's phone or email?

Ascendis Questions

News

Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath - BioSpace

Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath BioSpace

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 - GlobeNewswire

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 GlobeNewswire

Ascendis Pharma A/S (NASDAQ:ASND) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance

Ascendis Pharma A/S (NASDAQ:ASND) Just Released Its First-Quarter Earnings: Here's What Analysts Think Yahoo Finance

Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) - Seeking Alpha

Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) Seeking Alpha

Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace

Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause BioSpace

Ascendis Pharma price target raised to $254 by Cantor Fitzgerald - Investing.com Canada

Ascendis Pharma price target raised to $254 by Cantor Fitzgerald Investing.com Canada

Summit Therapeutics Signs Sublease with Ascendis Pharma - TipRanks

Summit Therapeutics Signs Sublease with Ascendis Pharma TipRanks

News Briefs: Ascendis’ Yorvipath Is Now Available - AIS Health

News Briefs: Ascendis’ Yorvipath Is Now Available AIS Health

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires? - Yahoo Finance

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires? Yahoo Finance

Ascendis Consulting Accelerates Growth with Pencilz Labs Merger - PRWeb

Ascendis Consulting Accelerates Growth with Pencilz Labs Merger PRWeb

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist - Fierce Biotech

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist Fierce Biotech

New Data Shows Improvements in Growth and Bone Morphometry - GlobeNewswire

New Data Shows Improvements in Growth and Bone Morphometry GlobeNewswire

Ascendis reports interim analysis outcomes from achondroplasia trial - Clinical Trials Arena

Ascendis reports interim analysis outcomes from achondroplasia trial Clinical Trials Arena

Kennedys advises Ascendis Pharma A/S (“Ascendis Pharma”) on exclusive distribution agreement - Kennedys Law

Kennedys advises Ascendis Pharma A/S (“Ascendis Pharma”) on exclusive distribution agreement Kennedys Law

Ascendis Health’s adverse TRP ruling set aside by high court - businessreport.co.za

Ascendis Health’s adverse TRP ruling set aside by high court businessreport.co.za

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewswire

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency GlobeNewswire

Ascendis Pharma Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Ascendis Pharma Second Quarter 2025 Earnings: Beats Expectations Yahoo Finance

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - Yahoo Finance

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 Yahoo Finance

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference - Yahoo Finance

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference Yahoo Finance

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA - Pharmaceutical Technology

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA Pharmaceutical Technology

Pendopharm and Ascendis to distribute hypoparathyroidism treatment - Pharmaceutical Technology

Pendopharm and Ascendis to distribute hypoparathyroidism treatment Pharmaceutical Technology

Ascendis Pharma Reports First Quarter 2025 Financial Results - GlobeNewswire

Ascendis Pharma Reports First Quarter 2025 Financial Results GlobeNewswire

Ascendis Submits Marketing Authorisation Application to the - GlobeNewswire

Ascendis Submits Marketing Authorisation Application to the GlobeNewswire

FDA approves Ascendis’ Skytrofa - The Pharma Letter

FDA approves Ascendis’ Skytrofa The Pharma Letter

Ascendis spins out new ophthalmology biotech Eyconis, gaining equity and biobucks - Fierce Biotech

Ascendis spins out new ophthalmology biotech Eyconis, gaining equity and biobucks Fierce Biotech

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire

Ascendis's YORVIPATH gets FDA approval for hypoparathyroidism - Pharmaceutical Technology

Ascendis's YORVIPATH gets FDA approval for hypoparathyroidism Pharmaceutical Technology

Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs - BioPharma Dive

Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs BioPharma Dive

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 - GlobeNewswire

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 GlobeNewswire

Biotech Leader Ascendis Pharma Set for Key Presentation at 2025 Wells Fargo Healthcare Conference - Stock Titan

Biotech Leader Ascendis Pharma Set for Key Presentation at 2025 Wells Fargo Healthcare Conference Stock Titan

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath - Fierce Pharma

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath Fierce Pharma

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) Seeking Alpha

Ascendis seeks European approval for dwarfism drug - medwatch.com

Ascendis seeks European approval for dwarfism drug medwatch.com

Ascendis spins out ophthalmology company; Gamida Cell eyes strategic options - Endpoints News

Ascendis spins out ophthalmology company; Gamida Cell eyes strategic options Endpoints News

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency - MedCity News

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency MedCity News

FDA turns back Ascendis' hormone drug over manufacturing issues - Fierce Pharma

FDA turns back Ascendis' hormone drug over manufacturing issues Fierce Pharma

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug - PMLiVE

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug PMLiVE

Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis - BioSpace

Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis BioSpace

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months - Fierce Pharma

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months Fierce Pharma

An Update On Ascendis Pharma's Path To Profitability (NASDAQ:ASND) - Seeking Alpha

An Update On Ascendis Pharma's Path To Profitability (NASDAQ:ASND) Seeking Alpha

Ascendis sells Japanese rights to Skytrofa and two other hormone drugs for $70M upfront - Fierce Biotech

Ascendis sells Japanese rights to Skytrofa and two other hormone drugs for $70M upfront Fierce Biotech

After manufacturing setback at FDA, Ascendis strikes $150M royalty deal on its first commercial drug - Fierce Pharma

After manufacturing setback at FDA, Ascendis strikes $150M royalty deal on its first commercial drug Fierce Pharma

Eyconis spins out from Ascendis Pharma, eyes breakthroughs with USD 150m backing - medwatch.com

Eyconis spins out from Ascendis Pharma, eyes breakthroughs with USD 150m backing medwatch.com

Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily

Why This Small Biotech Is Hammering BioMarin Today Investor's Business Daily

New Company Eyconis Formed to Develop Ascendis Pharma - GlobeNewswire

New Company Eyconis Formed to Develop Ascendis Pharma GlobeNewswire

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan - GlobeNewswire

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan GlobeNewswire

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada - PR Newswire Canada

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada PR Newswire Canada

From collapse to comeback at Ascendis Health: Lessons to learn says CEO Carl Neethling - IOL

From collapse to comeback at Ascendis Health: Lessons to learn says CEO Carl Neethling IOL

Ascendis Pharma A/S Announces U.S. Food and Drug - GlobeNewswire

Ascendis Pharma A/S Announces U.S. Food and Drug GlobeNewswire

Ascendis Pharma A/S Announces Extension of U.S. Food and - GlobeNewswire

Ascendis Pharma A/S Announces Extension of U.S. Food and GlobeNewswire

Big blow for Ascendis Health directors - Daily Investor

Big blow for Ascendis Health directors Daily Investor

Ascendis Health takeover investigated - Daily Investor

Ascendis Health takeover investigated Daily Investor

Attention value investors: Another smart acquisition for Ascendis Health - BizNews

Attention value investors: Another smart acquisition for Ascendis Health BizNews

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $264.00 - Defense World

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $264.00 Defense World

Top Ascendis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant